Falcon II is a fully automated intelligent next-generation sequencing (NGS) delivery platform unveiled by Novogene. At the forefront of providing cutting-edge NGS services, Novogene continues to improve service efficiency and strive for revolutionary breakthroughs in project turnaround time, data quality, and production stability via Falcon II.
Efficient 24/7/365 continuous operation
Process up to 384 samples per day maximally
Reduce overall production cycle by an average of 60%
Reduce manual handling by up to 70%
Increase monthly production capacity by 200%
Double system’s output stability
Cross contamination-free without human intervention
Two quality control steps in sample extraction and library construction respectively
Precise control and real-time remote monitoring by unique tracking code
Let’s Talk about Your NGS Project
（Fields marked with an * are required）
Novogene Corporation Inc.
8801 Folsom Blvd #290, Sacramento, CA 95826 (office)
Whole exome sequencing (WES) employs next-generation sequencing technology (NGS), which provides a cost-efficient alternative to whole genome sequencing (WGS). The human whole exome, composed by about 180,000 exons (protein-coding region of the genome) accounts for only 1-2% of the human genome, but up to 85% of the disease-related mutations associated with Mendelian disorders occur in these regions . By targeting these regions, human whole exome sequencing (hWES) provides an in-depth sequencing and analysis approach to indicate genome variants, germline mutations, somatic mutations, and pathogenic mechanisms. hWES service supports a broad range of studies for researchers, including genetic disease-related variants, complex diseases, cancer research, or human population genetics.